Endogenex
Plymouth
About Endogenex
Endogenex develops an endoscopic procedure to help patients with type 2 diabetes regain control of their blood glucose levels. Established in 2017, Endogenex has developed a novel therapy that utilizes pulsed electric fields to promote regeneration of the duodenal mucosa for improvement in glycemic control in patients with T2D.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 11 – 50
- Total funding: $163.0M
- Funding stage: Late Stage Venture
- Last round: Series C (Mar 2026)
- Website: endogenex.com
- Phone: +1 763 251-6820
Industries & Categories
Health Care, Medical Device, Therapeutics
Social Profiles
Canonical: https://fsome.com/organization/endogenex-68766 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.